Oral S-1 plus hepatic arterial infusion chemotherapy with gemcitabine for postoperative liver metastasis from pancreatic cancer

Oral S-1 plus hepatic arterial infusion chemotherapy with gemcitabine for postoperative liver metastasis from pancreatic cancer - Oral S-1 + GEM HAI chemotherapy

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000011060

Enrollment

Registered

2013-07-01

Start date

2011-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Postoperative liver metastases from pancreatic cancer

Interventions

gemcitabine

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Postoperative liver metstases from pancreatic cancer

Exclusion criteria

Exclusion criteria: Another metastatic lesions.

Design outcomes

Primary

Measure	Time frame
Prolongation of overall survival	—

Countries

Japan

Contacts

Public ContactHidehiro Tajima

Kanazawa University Hospital Hepato-Biliary-Pancreatic Surgery

hidetaji@staff.kanazawa-u.ac.jp076-265-2362

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026